Publicaciones en las que colabora con Miguel Ángel Sanz Alonso (15)

2015

  1. Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia

    Annals of Hematology, Vol. 94, Núm. 8

2011

  1. Recomendaciones para el tratamiento de las infecciones f́ngicas invasoras causadas por hongos filamentosos en pacientes hematológicos

    Revista Espanola de Quimioterapia, Vol. 24, Núm. 4, pp. 263-270

2010

  1. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome

    Blood, Vol. 115, Núm. 25, pp. 5137-5146

2009

  1. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

    Haematologica, Vol. 94, Núm. 9, pp. 1242-1249

2008

  1. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

    Blood, Vol. 111, Núm. 7, pp. 3395-3402

2007

  1. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention

    Leukemia, Vol. 21, Núm. 3, pp. 446-452

2004

  1. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

    Blood, Vol. 104, Núm. 12, pp. 3490-3493

2003

  1. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia

    Haematologica, Vol. 88, Núm. 11, pp. 1213-1220

2001

  1. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA

    Haematologica, Vol. 86, Núm. 8, pp. 807-813

  2. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group

    British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103

  3. Response to Lengfelder et al

    Leukemia

  4. Uncertain role of increased intensity chemotherapy with high-dose cytarabine in acute promyelocytic leukemia

    Leukemia

2000

  1. Definition of relapse risk and role of nonanthracycline drags for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups

    Blood, Vol. 96, Núm. 4, pp. 1247-1253

1999

  1. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia

    Blood, Vol. 94, Núm. 9, pp. 3015-3021

1998

  1. All-trans-retinoic acid in acute promyelocytic leukemia [3] (multiple letters)

    New England Journal of Medicine